Cortisone Withdrawal Syndrome: Management Protocol
When glucocorticoid withdrawal syndrome occurs during tapering, temporarily increase the glucocorticoid dose back to the most recently tolerated level and extend the tapering duration over a longer period. 1
Understanding Glucocorticoid Withdrawal Syndrome
Glucocorticoid withdrawal syndrome (GWS) is a distinct clinical entity that occurs when reducing glucocorticoid doses within the supraphysiologic range—meaning it happens while patients are still on doses above physiologic replacement (>4-6 mg prednisone equivalent daily). Critically, GWS is not due to adrenal insufficiency since the total daily dose remains supraphysiologic. 1
The syndrome manifests with symptoms including fatigue, myalgias, arthralgias, mood disturbances, and malaise that mimic both the underlying disease and adrenal insufficiency, making clinical differentiation challenging.
Structured Tapering Protocol
Initial Tapering Phase (Supraphysiologic Doses)
Taper glucocorticoids gradually down to physiologic dose equivalent (4-6 mg prednisone daily) while the underlying disease remains controlled. 1 The tapering rate should be guided by:
- Patient tolerance of withdrawal symptoms
- Disease activity status (must be quiescent)
- Duration of prior glucocorticoid exposure (longer exposure requires slower taper)
Do not perform adrenal function testing while patients remain on supraphysiologic doses—testing is inappropriate and not indicated at this stage. 1
Managing Withdrawal Symptoms During Taper
When GWS symptoms develop:
- Immediately increase the dose back to the previous well-tolerated level 1
- Extend the tapering timeline with smaller dose decrements
- Provide patient education and reassurance that symptoms are expected, temporary, and indicate physical dependence rather than disease flare 2, 3
- Consider switching from long-acting agents (dexamethasone, betamethasone) to shorter-acting glucocorticoids (hydrocortisone, prednisone) 1
Physiologic Dose Phase (≤4-6 mg Prednisone)
Once reaching physiologic dose equivalent, you have two evidence-based options 1:
Option 1 (Clinical Monitoring):
- Continue gradual tapering with close clinical surveillance
- Monitor for signs/symptoms of adrenal insufficiency (not withdrawal syndrome)
- Proceed to discontinuation if asymptomatic
Option 2 (Biochemical Confirmation):
- Measure morning serum cortisol (8:00-9:00 AM, 24 hours after last glucocorticoid dose) 1
- Interpret results as a continuum:
- >300 nmol/L (10 μg/dL): HPA axis recovered, safe to discontinue
- 150-300 nmol/L (5-10 μg/dL): Continue physiologic dose, retest in weeks to months
- <150 nmol/L (5 μg/dL): Continue physiologic dose, retest after several months
Critical Nuances and Pitfalls
The HPA axis remains suppressed even at physiologic doses. Recent evidence demonstrates that each 1 mg reduction in prednisolone (from ≤5 mg) increases morning cortisol by 48.8 nmol/L, with successful discontinuation achieved even in patients with nadir cortisol <28 nmol/L. 4 This challenges traditional cortisol thresholds and supports that tapering itself enables HPA axis recovery rather than waiting for recovery before tapering.
Never reduce below physiologic replacement doses (4-6 mg prednisone equivalent) if adrenal insufficiency is documented, as this ensures adequate replacement while still providing stimulus for HPA axis recovery. 1
Avoid routine dynamic testing (ACTH stimulation tests) during glucocorticoid tapering—morning cortisol is sufficient for initial assessment. 1 Dynamic testing may be considered only in specific circumstances when clinical judgment suggests inadequate cortisol response to major stress.
Duration Considerations
- Short-term therapy (<3-4 weeks): No taper needed regardless of dose; stop abruptly with low concern for HPA suppression 1
- Long-term therapy (>3-4 weeks at supraphysiologic doses): Requires structured tapering protocol 1
Special Populations
Patients with signs of exogenous Cushing syndrome should be assumed to have glucocorticoid-induced adrenal insufficiency and managed accordingly. 1
If HPA axis fails to recover after one year on physiologic doses, refer to endocrinology. 1 Similarly, any patient with history of adrenal crisis warrants endocrine specialist evaluation. 1
FDA Guidance
The FDA label emphasizes that drug-induced secondary adrenocortical insufficiency may be minimized by gradual dose reduction, with this relative insufficiency potentially persisting for months after discontinuation. During any stressful situation in this period, hormone therapy should be reinstituted. When stopping after long-term therapy, withdraw gradually rather than abruptly. 5